Latest Industry Insights

AI is revolutionizing biotechnology innovation, but industry stakeholders must work together to mitigate its risks. In this article, Adam Clore explores the role of nucleic acid biosecurity screening tools and how they can be improved.

Discover how scalable, human-based in vitro models are reshaping discovery pipelines, balancing complexity with reproducibility, and enabling new kinds of experimentation that go beyond the limits of animal research.

In this opinion piece, Dr. Stella Vnook explores how cell and gene therapy leaders are adapting to today’s financial and regulatory headwinds, offering actionable insights into how biotech CEOs are rethinking capital strategy.

As global scientific and regulatory landscapes shift, companies across the life sciences sector are under growing pressure to adapt. Hear how Phenomenex are taking a proactive approach.

Explore why cell and gene therapy manufacturing failures are now a leading cause of FDA rejections and how to avoid them.

Discover how AI-powered ADMET modeling can enable the prediction of toxicity and pharmacokinetics with depth, transparency and scientific rigor.

Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and scalable alternatives.

Technology Networks spoke with Stefan Foser, vice president of global pharma at Bruker, to explore how they integrate instrumentation, software and consumables to support early-stage pharma innovation.

From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and other diseases. Offering a new path to degrade targets once thought undruggable.

Explore how multiomics research combines genomics, proteomics, and transcriptomics to offer new insights in disease modeling and therapeutic advancements.